SCHEDULE: Dodge & Cox Holds 12.5% Stake in Zimmer Biomet

Dodge & Cox reports a beneficial ownership of 24,124,735 shares, representing 12.5% of Zimmer Biomet Holdings, Inc. common stock as of June 30, 2026.

Summary

• Dodge & Cox has filed a Schedule 13G, indicating their beneficial ownership of Zimmer Biomet Holdings, Inc. common stock.
• As of June 30, 2026, Dodge & Cox beneficially owns 24,124,735 shares, which constitutes 12.5% of the class of securities.
• The filing specifies sole voting power for 22,808,935 shares and sole dispositive power for 24,124,735 shares.
• Dodge & Cox Stock Fund, an investment company managed by Dodge & Cox, holds 15,549,900 shares, representing 8.0% of the class.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting a significant but stable institutional holding without immediate indications of aggressive action or distress.

Positives

• Dodge & Cox, a significant investment manager, maintains a substantial stake in Zimmer Biomet, suggesting confidence in the company's long-term prospects.
• The holding of 12.5% indicates a significant institutional investor's commitment.
• The Dodge & Cox Stock Fund's specific holding of 8.0% further details the composition of this large investment.

Negatives

• The filing is a routine disclosure of beneficial ownership and does not inherently signal any negative developments.
• No specific negative financial or operational data is presented in this type of filing.

Risks

• The filing does not explicitly mention any risks. However, as with any large institutional holding, a future decision by Dodge & Cox to significantly reduce its position could impact the stock price.

Future Outlook

This filing is a disclosure of current ownership and does not contain forward-looking statements or guidance regarding Zimmer Biomet's future performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that institutional ownership filings like this Schedule 13G are common and provide transparency into significant holdings. Dodge & Cox is a well-established investment management firm, and their substantial stake in Zimmer Biomet, a major player in the medical device industry, is noteworthy.

Comparison to Industry Standards

• Institutional ownership percentages vary widely by industry and company maturity. A 12.5% stake by a single investment manager is considered a significant holding, often indicative of a long-term investment strategy.
• Competitors in the orthopedic device market, such as Stryker and Johnson & Johnson's medical device segment, also have substantial institutional ownership, though specific percentages fluctuate based on market conditions and investor sentiment.

Stakeholder Impact

• Shareholders: The continued significant holding by a major institutional investor like Dodge & Cox can be viewed positively, potentially signaling stability and confidence in the company's value.
• Management: The filing confirms that Dodge & Cox is not acquiring shares with the intent to influence or change control, which is a standard certification for this type of filing.

Next Steps

• Dodge & Cox will continue to monitor its investment in Zimmer Biomet and may adjust its holdings based on market conditions and company performance.
• Zimmer Biomet will continue its operations in the medical device sector.

Key Dates

Keywords

Zimmer Biomet Holdings, Dodge & Cox, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Management